A randomized, double-blind, double-dummy, active-controlled, parallel group study of a single dose of ACZ885 [canakinumab] in hospitalized patients with acute gout.

Trial Profile

A randomized, double-blind, double-dummy, active-controlled, parallel group study of a single dose of ACZ885 [canakinumab] in hospitalized patients with acute gout.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jan 2013

At a glance

  • Drugs Canakinumab (Primary) ; Dexamethasone
  • Indications Gouty arthritis
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 15 Mar 2012 Actual end date 23 Oct 2009 added as reported by EudraCT.
    • 03 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Mar 2010 Actual number of patients (6) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top